Abstract
Allopurinol is widely used in the treatment of gout. The main metabolic pathway of allopurinol is its oxidation to oxypurinol. Pyrazinamide is an antituberculous drug. One of the main metabolic pathways of pyrazinamide is its oxidation to 5-hydroxypyrazinamide. The oxidation of allopurinol and pyrazinamide is known to be attributed to xanthine oxidase1, 2. However, it has been suggested that aldehyde oxidase also participates in the oxidation of these agents3, 4. Therefore, we investigated whether aldehyde oxidase plays a role in the oxidation of allopurinol and pyrazinamide by in vivo and in vitro studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G.B. Elion. Allopurinol and other inhibitors of urate synthesis. In: Uric Acid (Eds.W.N. Kelley and I.M. Weiner), pp.485. Springer, Berlin (1978).
G.A.C. Murrell and W.G. Rapeport. Clinical pharmacokinetics of allopurinol. Clin pharmacokinet 11:343(1986).
D.G. Johns. Human liver aldehyde oxidase: differential inhibition of oxidation of changed and unchanged substrates. J. Clin Invest 46:1492(1967).
T.A. Krenitzky, S.M. Neil, G.B. Elion and G.H. Hitchings. A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys 150:585(1972).
S. Sato, K. Tatsumi, T. Nishino. A novel xanthine dehydrogenase inhibitor(BOF-4272). Adv Exp Med Biol 309A:135(1991).
T. Yamamoto, Y. Moriwaki, S. Takahashi, T. Hada and K. Higashino. Rapid and simultaneous determination of pyrazinamide and its major metabolites in human plasma by high-performance liquid chromatography. J. Chromaiogr 413:342 (1987).
J.G.P. Stell, A.J. Warne and C. Lee-Woolley. Purification of rabbit liver aldehyd oxidase by affinity chromatography on Benzamidine Sepharose6B. J. Chromatogr 475:363(1989).
J. Kurth and A. Kubiciel. Method zur photometrischen Bestimmung der Aktivität von Aldehydoxydase. Biomed Biochim Acta 43:1223 (1984).
T. Yamamoto, Y. Moriwaki, S. Takahashi, T. Hada and K. Higashino. Separation of hypoxanthine and xanthine from pyrazinamide and its metabolites in plasma and urine by high-performance liquid chromatography. J. Chromatogr 382:270(1986).
Y. Yonetani and K. Iwaki. Effects of uricosuric drugs and diuretics on uric acid excretion in oxonate-treated rats. Jpn J Pharmacol 33:947(1983).
T. Yamamoto, Y. Moriwaki, S. Takahashi, T. Hada and K. Higashino. Study of the metabolism of pyrazinamide using a high-performance liquid ChromatographiC analysis of urine samplts. Anal Biochem 160:346(1987).
T. Yamamoto, Y. Moriwaki, S. Takahashi, T. Hada and K. Higashino. In vitro conversion of pyrazinamide into 5-hydroxypyrazinamide and that of pyrazinoic acid into 5-hydroxypyrazinoic acid by xanthine oxidase from human liver. Biochem Pharmacol 36:3317(1987).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Nasako, Y. et al. (1995). In Vitro and In Vivo Study on the Conversion of Allopurinol and Pyrazinamide. In: Sahota, A., Taylor, M.W. (eds) Purine and Pyrimidine Metabolism in Man VIII. Advances in Experimental Medicine and Biology, vol 370. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2584-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2584-4_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6105-3
Online ISBN: 978-1-4615-2584-4
eBook Packages: Springer Book Archive